Regulation Nation: How the Industry is Responding to FDA Inquiry

The United States of America’s Food and Drug Administration has opened its door to receive ideas, responses, and suggestions on how cannabis extracts should be handled and controlled across its state-wide production. Through a collective sorting of reactions, the FDA was able to accumulate around 4000 responses.

The ones who sent suggestions and recommendations mainly came from the local state health departments and private sectors manufacturing cannabidiol. Other pertinent respondents also include the American Medical Association, among others. 

FDA is placing a focus mark at the CBD extracts found in hemp and marijuana varieties as a significant retaliation to the exponential increase in demand for the sales of CBD.

As such, the agency aims to hasten their regulation of this sudden accumulation of public interest in treatments and medication involving cannabidiols. 

From a Comprehensive Report from Hemp Industry Daily, here’s what CBD manufactures, constituents, and private sectors have to say about the issue.

Kazmira co-founder Pulak Sharma:

“Clamp down on operators manufacturing hemp oils with contaminants…”

Furthermore, he added that he was particularly pointing at the danger of dilution. He asserts that this kind of practice is not the solution.

Irwin Naturals:

They have said that the individuals who are continuously exposed to products with higher amounts of CBD and other varieties should be observed to ensure that they are safe and secure.

American Medical Association:

Their recommendation centers on the establishment of a program to determine CBD impact. Specifically, they intend to push through with “ongoing surveillance.”

 “Surveillance should include… [the] impact on patterns of use, traffic fatalities and injuries, [emergency department] visits and hospitalizations, unintentional exposures, exposure to secondhand smoke[,] and cannabis-related treatment admissions.”

Moreover, they wish to place much attention to children and pregnant women in the whole regulation.

University of California, VP for Research and Graduate Studies:

The professor has explained a concern about the laws which restrict cannabis research due to local medical and recreational legislation. He further explains that extensive research on cannabis should be expanded, one which is allowed and unrestricted by law. 

Furthermore, research should be allowed to study cannabis found in the “real world,” especially those dispensed in retail outlets and drugstores. Such is made to ensure that their studies do not actually impact CBD solely in theory.

American Psychiatric Association:

The agency has emphasized that while there is still no direct evidence pinpointing the correlation of CBD to the treatment of patients with psychotic disorders, there is still a need to regulate the surge of CBD products in the market correctly.

Plant Life Group:

They have told the FDA to not only focus on pharmacology related consumer path but other product variations as well. This way, consumer interest would flock to other hemp products with non-traceable levels of active CBD.

National Association of Chain Drug Stores:

Their consumers and target market still face much confusion about the products with CBD; that’s why they are currently asking the FDA to “act swiftly.”

Hemp Farmer George Pertot:

“All-natural, full-spectrum unadulterated hemp oil should be classified as a food supplement and a dietary supplement, only in its pure unadulterated form as full-spectrum crude hemp oil or distillate only.”

Likewise, he wishes the FDA to control and subject foreign CBD products through rigorous and strict standards before importing and selling it in the country. His reasoning for this claim is to protect the population from outdated and illegal pesticides from plants and ferns grown abroad. 

Vermont Agency of Agriculture, Food, and Markets Secretary Anson Tebbetts:

“As the EPA is moving toward developing tolerances for hemp crops … disallowing hemp and hemp-derived products in food removes the ability to effectively regulate pesticide tolerances at both the state and federal level.”

Like the other manufacturers, Tebbetts simply wants to stray away from harmful pesticides and chemicals to be mixed into the CBD products.

On the Edge

These are only some of the many responses sent to the US FDA for suggestions on how to regulate CBD in the US.

In the end, what matters is that everyone has generously offered noteworthy suggestions. What’s left for the FDA is carefully calculate their next move to ensure the safety of every consumer and manufacturer of CBD. For the CBD constituents, the most important regulation that the FDA can do is to secure the health of individuals using CBD products.